先前的研究缺乏关于库珀单抗治疗晚期皮肤鳞状细胞癌初次反应的预测因素。研究已发现IL-6影响免疫细胞群体，影响肿瘤发展。因此，我们的研究旨在探究在治疗前和治疗期间血清IL-6水平的预测意义。在一项回顾性研究中，血清IL-6水平与临床结果相关联。总的来说，有39名患者接受了治疗。高水平的血清IL-6（>5.6pg/ml）与更差的生存率（45.1%对0死亡；OS:16.1±1.5对20.8±0个月，95% CI为13,046至19,184）和更短的PFS（10.3 ± 1.9对18.9 ± 1.5个月；95% CI为3433至10,133）在接受库珀单抗治疗的晚期CSCC患者中相关。此外，在接受库珀单抗治疗后，无论基础水平如何，IL-6水平升高的患者治疗反应较差，而水平降低或稳定的患者治疗反应较好。治疗前和库珀单抗免疫疗法后的血清IL-6水平变化可能对晚期切除性鳞状细胞癌患者具有预测意义。©2023. 作者（们）。

Prognostic factors for initial response of advanced cutaneous squamous cell carcinoma to cemiplimab treatment are lacking. Il-6 has been found to affect immune cell populations which impact tumor development. The aim was to investigate the prognostic significance of IL-6 serum levels before and during treatment.Serum levels of IL-6 were correlated with clinical outcomes in a retrospective study.Overall, 39 patients were enrolled. High serum levels of IL-6 (> 5.6 pg/ml) were associated with poorer survival (45.1% vs 0 deaths; OS: 16.1 ± 1.5 vs 20.8 ± 0 months, 95% CI 13,046 to 19,184) and shorter PFS (10.3 ± 1.9 vs 18.9 ± 1.5 months; 95% CI 3433 to 10,133) in patients with advanced CSCC treated with cemiplimab. In addition, patients whose IL-6 level increased after treatment with cemiplimab, independently of the basal level, had a poorer response to treatment than patients whose level was reduced or stable after immunotherapy.Serum levels of IL-6 at baseline and changes after cemiplimab immunotherapy may have a prognostic significance in patients with advanced cutaneous squamous cell carcinoma.© 2023. The Author(s).